Mitochondria and Cancer: From Basic Science to Clinical Applications – Understanding Pathogenesis, Therapy Resistance and Disease Relapse

Mitochondria and Cancer: From Basic Science to Clinical Applications―Understanding Pathogenesis, Therapy Resistance, and Disease Relapse offers comprehensive perspectives about the role of mitochondria in cancer biology and treatment. This book integrates fundamental scientific knowledge with clinical relevance, presenting recent findings that will engage oncology researchers and provide valuable recommendations for cancer prevention and prognosis. In response to the rising global cancer incidence, this book serves as a comprehensive guide to mitochondrial metabolism in oncology, furthering cancer study and management. It explores a wide range of topics that highlight the multifaceted role of mitochondria in cancer, including tumor microenvironment, cancer stem cells, microbiota, resistance mechanisms, mitochondria-enhancing strategies, and targeted therapies. It includes technical details, research findings, and discussions on the implications of mitochondrial research in cancer treatment and management. Its distinguishing aspects include its comprehensive coverage and diverse perspectives from global experts, providing a well-rounded view of current research.

• Delivers an in-depth analysis of how mitochondrial alterations contribute to cancer formation, disease progression, and resistance to conventional and targeted therapies
• Presents comprehensive insights into the dynamic interactions between mitochondria in cancer cells, tumor microenvironment, and microbiota, highlighting their collective influence on cancer progression and therapeutic outcomes
• Combines fundamental scientific knowledge with clinical relevance, covering a wide array of topics from mitochondrial metabolism to innovative therapeutic strategies

Dr. Farzad Taghizadeh-Hesary is an Assistant Professor of Radiation Oncology at Iran University of Medical Sciences, specializing in oncology, radiobiology, and cancer metabolism. He earned his M.D. in 2015 from IUMS and completed a Radiation Oncology residency at Shahid Beheshti University of Medical Sciences, ranking among the top graduates nationally. His thesis examined late toxicities after IMRT for nasopharyngeal carcinoma, reflecting a commitment to precision radiotherapy.

His expertise spans clinical and academic oncology, with a focus on tumor microenvironment and mitochondrial metabolism in cancer. He has published more than 80 peer-reviewed articles and serves on editorial boards including BMC Cancer and PLoS ONE. Awards include the Razi Medical Science Research Prize and the Outstanding Reviewer Award from JCO Clinical Cancer Informatics; Publons Academy ranked him the top global Radiation Oncology reviewer in 2021.

His research centers on personalized radiotherapy, cancer immunotherapy, and metabolic interventions targeting mitochondrial dysfunction, advancing translational oncology

Dr. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. He has 5 years of teaching experience. He has achieved 100+ publications in international and national accredited reputed journals. He has expertise in drug delivery, nanotechnology, and targeted treatment strategies. Recently, he was honored to be in the World’s Top 2% Scientists by prestigious Stanford University, CA, United States, and Elsevier in 2025.

Dr. Babak Behnam has completed his PhD degree at the University College London (UCL) in Human Genetics. Then he served as postdoctoral research fellow at the University of Michigan School of Medicine and University of Central Florida (UCF). He joined the Undiagnosed Disease Program (UDP) at NIH while doing an American Board of Medical Genetics and Genomic in clinical biochemical laboratory genetics at NHGRI, NIH. He joined NSF International as a clinical research organization. Dr. Behnam has published more than 70 peer-reviewed papers and has nine patents to his name throughout his career; also, has served as an Editorial Board Member of several scientific journals. He has enthusiasm in translational research, neuroscience & neurogenetics, and biochemical & molecular mechanisms utilizing advanced technological improvements in biochemical genetics, genomics, and NGS platforms. Also, he has an experience and interest in clinical research, and regulatory and scientific analysis of clinical trials.

Dr. Vliora Maria is a Molecular Biologist with extensive background in molecular biology and integrative physiology. She has previously studied mutations of immunoglobulins in Chronic Lymphocytic Leukemia patients, and ALK mutations and downstream signaling in Neuroblastoma. Dr. Vliora has a PhD in Biomedical Research from University of Thessaly, Greece and University of Brescia, Italy. She has worked on the development of biocompatible/biodegradable bioscaffolds for targeting adipose tissue as well as on potential nanomedical treatments for brain tumors as well as blood malignancies. Her research work is now focusing on environmental influences that can affect human health and on the use of novel biodegradable bio-scaffolds for allografting adipose stem cells in humans. She collaborated with reputable organizations (WHO, ILO) on projects aiming to enhance human health and wellbeing. She now works as a Project Manager on EU funded projects.